News

The point-of-care model was proven to work better than the referral model when it came to ensuring that patients undergo the genetic screening that they needed.

Here are the top 5 Oncology Nursing News stories for March 2019.

The Food and Drug Administration decided to keep the device on the market, but wants to know more about the illnesses they may potentially be linked to.

It is better to introduce the topic sooner rather than later, according to one expert.

Ninety percent of patients with cancer enter their first oncology appointment with a nutritional issue, according to Susan Bratton. However, Savor Health, who works in conjunctions with Merck’s Your Cancer Game Plan, has set out to combat just that.

Nurses and other healthcare providers can mitigate emotional distress and improve quality of life in patients with cancer by having earlier and more thorough conversations about their care, according to a recent study conducted at the Dana-Farber Cancer Institute.

The FDA has granted a breakthrough therapy designation to the combination of ivosidenib (Tibsovo) and azacitidine for the treatment of newly diagnosed patients with IDH1-mutant acute myeloid leukemia (AML) ≥75 years old or are ineligible for intensive induction chemotherapy.

The FDA announced today that it is working to update mammography regulations, expanding the amount of information that mammography facilities must give patients and healthcare professionals. In turn, this would result in more informed decision-making – especially when it comes to breast cancer diagnoses.

While there are some exciting advances coming down the pipeline, there is still much work to do when it comes to the molecular diagnosis of patients with renal cell carcinoma (RCC), explained David I. Quinn, MBBS, PhD, FRACP, FACP.

Wells A. Messersmith, MD, co-director of the developmental therapeutics program at the University of Colorado Cancer Center, said work in this area is needed to fill the knowledge gaps in metastatic CRC, which has a 5-year survival rate of just 11%.

Check out this infographic exploring 5 ways oncology nurses can do their part to improve cancer care for their patients.

Oncology nurses must discuss treatment options and adverse events with their patients who have ovarian cancer.

Man’s best friend may eventually be healthcare’s best friend.

Team V raises thousands to support cancer research

Fourth-Generation, Family-Owned Egg and Feed Farm Joins Local Cycling Event to Achieve Victory Over Cancer®

The FDA has granted an approval to the combination of atezolizumab (Tecentriq) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

An expert discusses the role oncology nurses play in managing the adverse events of patients with breast cancer.

Listen to the first-ever episode of the CURE Talks Cancer Podcast: Nursing Edition.

It’s an exciting time in the world of triple-negative breast cancer (TNBC), with treatments becoming more personalized to individual cancer subtypes, explained Adam Brufsky, MD, PhD.

Financial distress puts a major burden on patients with cancer and their families. And while there are numerous resources that nurses can share with their patients to help with co-pays and other money-related issues, they are not widely discussed.

Clinical trials can be very beneficial to patients and their families. However, barriers still exist in enrolling patients.

The FDA has granted an approval to PF-05280014 (Trazimera; trastuzumab-qyyp), a trastuzumab (Herceptin) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

More patients are surviving long after their cancer diagnoses, putting a new emphasis on survivorship care planning, explained Deborah A. Boyle, MSN, RN, AOCNS, FAAN.

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.

The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)